President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy.

Supply problems and insurance complications have made it difficult for many patients to start and stay on new prescription medications used to treat obesity.